This Barclays research summary covers C4 Therapeutics, assigning it an 'Overweight' rating with a focus on its Cemsidomide development in multiple myeloma.
Key Takeaways
- 1.C4 Therapeutics' development of Cemsidomide is a primary focus in the multiple myeloma treatment space.
Table of Contents
- Americas Small Cap Research Summary
- Company Research
- Publications Summary
- C4 Therapeutics: Boston Bus Tour: Cemsidomide Has the Potential To Be a Backbone Therapy in Multiple Myeloma
- Analyst(s) Certification(s)
- Important Disclosures
- Availability of Disclosures
- Risk Disclosure(s)
- Guide to the Barclays Fundamental Equity Research Rating System
- Industry View
- Distribution of Ratings
- Guide to the Barclays Research Price Target
- Types of investment recommendations produced by Barclays Equity Research
- Disclosure of other investment recommendations produced by Barclays Equity Research
- Legal entities involved in producing Barclays Research
- Disclaimer
- Sustainable Investing Related Research
- IRS Circular 230 Prepared Materials Disclaimer
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Etzer DaroutLukas Shumway
Securities
CCCC
Themes
BiotechnologyMultiple Myeloma Treatment
Regions
North AmericaUnited States